"Cancer treatment" from_date:2012

Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * Policies * * Accessibility * Journals LibraryNHS NIHR - National Institute for Health Research Select EME GHR HSDR HTA PGfAR PHR Advanced

One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT Text onlyJournals LibraryNHS NIHR - National Institute for Health and Care ResearchSelectEMEGHRHSDRHTAPGfARPHR AdvancedJournalsEfficacy and Mechanism EvaluationGlobal Health ResearchHealth and Social Care Delivery ResearchHealth Technology AssessmentProgramme cancer treatment: the FAST-Forward phase III RCTAdrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, Mark A Sydenham, David J Bloomfield, Charlie Chan, Suzy Cleator, Charlotte E Coles, Ellen Donovan, Helen Fleming, David Glynn, Andrew Goodman, Susan Griffin, Penelope Hopwood, Anna M Kirby, Cliona C Kirwan, Zohal Nabi, Jaymini Patel, Elinor Sawyer, Navita Somaiah, Isabel Syndikus, Karen Venables

Interventions for preventing oral mucositis in people receiving cancer treatment: photobiomodulation. This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of photobiomodulation for the prevention of oral mucositis in people undergoing treatment for head and neck cancers, other solid cancers, and haematological cancers.

Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs Electronic self-reporting of adverse events for patients undergoing cancer treatment: the eRAPID research programme including two RCTs * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * * Accessibility * Journals

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition was published in June 2022. The guidelines were prepared while conforming as much as possible to the "Minds Manual

Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition Molecular testing to determine optimal therapies is essential for managing patients with colorectal cancer (CRC). In October 2022, the Japanese Society of Medical Oncology published the 5th edition of the Molecular Testing Guideline for Colorectal Cancer Treatment

Impact of physical activity on the adverse effects of cancer and cancer treatments in adults 1 Impact of physical activity on the adverse effects of cancer and cancer treatments in adults English summary Une production de l’Institut national d’excellence en santé et en services sociaux (INESSS) APRIL 2023 1 SUMMARY Impact of physical activity on the adverse effects of cancer and cancer treatments in adults Introduction Although cancer is the leading cause of death in Québec, the advances in cancer treatments in recent years have considerably increased the chances of survival for those affected. However, these therapeutic advances have contributed to the occurrence of specific adverse effects in "survivors", a term referring to patients who have been diagnosed

SpaceOAR systems for rectum protection during prostate cancer treatment Published: 14 August 2023 Driving Better Decision-Making in Healthcare Page 1 When a SpaceOAR systems for rectum protection during prostate cancer treatment Technology Guidance from the MOH Medical Technology Advisory Committee Guidance Recommendations The Ministry of Health’s Medical Technology Advisory Committee has not recommended subsidy for SpaceOAR systems (SpaceOAR and SpaceOAR Vue Systems) for rectum protection during prostate cancer treatment. Funding status SpaceOAR systems are not recommended for subsidy in patients with the abovementioned indications. Technology Guidance Driving Better Decision-Making in Healthcare Page 2 Factors considered to inform

Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment Skip to main contentAn official website of the United States governmentEspañolMenuSearchHome Cancer Types Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Health Professional Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional VersionPrintEmailOvarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional VersionGo to Patient VersionON THIS PAGEGeneral Information About Ovarian Epithelial Cancer, Fallopian Tube Cancer (FTC), and Primary Peritoneal Cancer (PPC)Cellular Classification of Ovarian Epithelial Cancer, FTC, and PPCStage Information for Ovarian Epithelial Cancer, FTC, and PPCTreatment Option

Influenza Immunization for Adult and Pediatric Patients Undergoing Cancer Treatment Influenza Immunization for Adult and Pediatric Patients Undergoing Cancer Treatment Effective Date: November, 2021 Clinical Practice Guideline SUPP-002 – Version 13 www.ahs.ca/guru Guideline Resource Unit guru@ahs.ca the Influenza Immunization Information for Health Professionals webpage. For information specific to COVID-19 immunization for Alberta cancer patients and families, please refer to COVID-19 and Cancer Treatment. For general COVID-19 immunization information, please refer to Health Professional Immunization Information (COVID-19). The 2021/2022 standard and high dose quadrivalent inactivated influenza vaccines

AIM Cancer Treatment Pathways 8600 West Bryn Mawr Avenue Appropriate.Safe.Affordable South Tower – Suite 800 Chicago, IL 60631 © 2022 AIM Specialty Health www.aimspecialtyhealth.com 9075-0822 AIM Cancer Treatment Pathways EFFECTIVE AUGUST 1, 2022 LAST REVIEWED MAY 10, 2022 Note: Pathways are independent of specific health plan medical policy by health plan formularies, medical policies, or preferred product rules. Effective August 1, 2022 3 TABLE OF CONTENTS AIM Cancer Treatment Pathways 4 Bladder Cancer (Urothelial) Pathways 5 Breast Cancer Pathways: Neoadjuvant and Adjuvant (Non-Endocrine) 9 Breast Cancer Pathways: Advanced/Metastatic Disease 13 Breast Cancer Pathways: Endocrine Therapy for Advanced/Metastatic Disease 19 Chronic

Multimodality Imaging for Cardiac Surveillance of Cancer Treatment in Children: Recommendations From the American Society of Echocardiography GUIDELINES AND STANDARDSMultimodality Imaging for CardiacSurveillance of Cancer Treatment inChildren: Recommendations From theAmerican Society of EchocardiographyLuc Mertens, MD, PhD, FASE (Chair), Gautam Singh, MD, FASE (Co-chair), Saro Armenian, DO, MPH to monitor car-diac function in adults undergoing cancer treatment are available.1,2Children with cancer, however, require a different imaging approach.Screening and detection strategies in younger children have largelyrelied on longitudinal monitoring of echocardiographic measures ofleft ventricle (LV) systolic function, mainly fractional shortening (FS)and ejection fraction (EF). Despite the important

DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment Kidneys of newborn (but not adult) mice are normally high permissive for polyomavirus (Py) infection and readily establish persistent infections. We have proposed that ongoing cellular differentiation, which occurs in newborn mice, may be necessary for a high level of in vivo Py

Child health: Physical activity during childhood cancer treatment: survivors want it, parents want it, peers can facilitate it Skip to main contentSubscribe Log In Basket Search Latest content Current issue Archive Write for Us About EBN BlogYou are hereHome Archive Volume 26, Issue 2Email alertsArticleTextArticleinfoCitationToolsShareRapid ResponsesArticlemetricsAlertsPDFCommentaryChild healthPhysical activity during childhood cancer treatment: survivors want it, parents want it, peers can facilitate itDavid Mizrahi1, Alexandra Martiniuk1,2,3,4Correspondence to Dr David Mizrahi, Daffodil Centre, The University of Sydney, Sydney, NSW 2006, Australia; david.mizrahi@sydney.edu.auhttps://doi.org/10.1136/ebnurs-2022-103634Statistics from Altmetric.comSee more detailsPosted by 14 X usersOn 1

Exercise, Diet, and Weight Management During Cancer Treatment Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline | Journal of Clinical Oncology Skip to main content Log In submission complete iconSubmit envelopeE-Alerts cartCart OpenAthens/Shibboleth »Enter words / phrases / DOI / ISBN / authors / keywords / etc. Search in: Search This Journal Search ASCO Journals & TOOLSExport Citation Track Citation Add To Favorites * Rights & Permissions COMPANION ARTICLESNo companion articles ARTICLE CITATIONDOI: 10.1200/JCO.22.00687 Journal of Clinical Oncology - published online before print May 16, 2022PMID: 35576506Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline Jennifer A. Ligibel , MD1xJennifer A. LigibelSearch for articles

Use of Opioids for Adults with Pain from Cancer or Cancer Treatment Skip to main contentLog Insubmission complete iconSubmitenvelopeE-AlertscartCartEnter words / phrases / DOI / ISBN / authors / keywords / etc.Search in:Search ASCO JournalsAdvanced SearchMenu * ASCO Publications * Journal of Clinical Oncology * JCO Oncology Practice * JCO Global Oncology * JCO Clinical Cancer

Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) The sixth edition of the Japanese Gastric Cancer Treatment Guidelines was completed in July 2021, incorporating new evidence that emerged after publication of the previous edition. It consists of a text-based "Treatments" part and a "Clinical Questions" part including recommendations and explanations for clinical questions

Childhood Nasopharyngeal Cancer Treatment Skip to main contentAn official website of the United States governmentEspañolMenuSearchHome Cancer Types Head and Neck Cancer Health Professional Childhood Treatment Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional VersionPrintEmailChildhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional VersionGo to Patient trials for adolescents with rare cancers.Information about these tumors may also be found in sources relevant to adults with cancer, such as Nasopharyngeal Cancer Treatment (Adult).ReferencesSmith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010. [PUBMED Abstract]American Academy

Childhood Oral Cavity Cancer Treatment Skip to main contentAn official website of the United States governmentEspañolMenuSearchHome Cancer Types Head and Neck Cancer Health Professional Childhood Treatment Childhood Oral Cavity Cancer Treatment (PDQ®)–Health Professional VersionPrintEmailChildhood Oral Cavity Cancer Treatment (PDQ®)–Health Professional VersionGo to Patient VersionON cancers.Information about these tumors may also be found in sources relevant to adults with cancer, such as Lip and Oral Cavity Cancer Treatment (Adult).ReferencesSmith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010. [PUBMED Abstract]American Academy of Pediatrics: Standards for pediatric cancer

Cancer Treatment Pathways Proprietary © 2023 Carelon Medical Benefits Management, Inc. All rights reserved. carelon.com Status: Revised with last review Effective Date: 01-16-2023 Doc ID: 9075-0323 Last Review Date: 11-01-2022 Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules. Carelon Medical Benefits Management Cancer Treatment Pathways Cancer Treatment Pathways © 2023 Carelon Medical Benefits Management. All rights